abrdn Life Sciences Investors (NYSE:HQL) Shareholders to Receive $1.50 Quarterly Dividend

abrdn Life Sciences Investors (NYSE:HQL) announced a quarterly dividend on Tuesday, November 10th. Stockholders of record on Friday, November 20th will be paid a dividend of $1.50 per share on Tuesday, January 12th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 31.7%. The ex-dividend date of this dividend is Friday, November 20th.

abrdn Life Sciences Investors Trading Up 1.4%

Shares of NYSE:HQL traded up $0.26 during trading on Wednesday, hitting $18.93. 77,995 shares of the company’s stock traded hands, compared to its average volume of 127,762. The company has a 50-day moving average price of $18.62 and a 200-day moving average price of $18.28. abrdn Life Sciences Investors has a 52 week low of $15.66 and a 52 week high of $22.67.

Institutional Trading of abrdn Life Sciences Investors

Hedge funds have recently made changes to their positions in the business. Flagship Harbor Advisors LLC increased its stake in shares of abrdn Life Sciences Investors by 4.1% during the third quarter. Flagship Harbor Advisors LLC now owns 417,366 shares of the company’s stock worth $7,805,000 after purchasing an additional 16,601 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in abrdn Life Sciences Investors by 57.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 362,535 shares of the company’s stock valued at $5,898,000 after purchasing an additional 132,098 shares during the period. Advisors Asset Management Inc. bought a new stake in abrdn Life Sciences Investors in the 3rd quarter valued at about $3,907,000. Formidable Asset Management LLC grew its position in shares of abrdn Life Sciences Investors by 0.7% during the 3rd quarter. Formidable Asset Management LLC now owns 166,324 shares of the company’s stock worth $3,328,000 after purchasing an additional 1,081 shares in the last quarter. Finally, 180 Wealth Advisors LLC grew its position in shares of abrdn Life Sciences Investors by 2.2% during the 2nd quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock worth $3,058,000 after purchasing an additional 3,271 shares in the last quarter. 32.21% of the stock is owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors is a non-diversified, closed-end investment fund focused on companies in the life sciences and health care sectors. Rather than developing or selling products itself, the fund invests in businesses involved in areas such as biotechnology, pharmaceuticals, medical devices and related services. The fund seeks long-term capital appreciation through a portfolio that can include both publicly traded and privately held companies. Its investments may span U.S. and international markets.